Abstract
Introduction Infection caused by SARS-CoV-2 has been shown to lead to significant procoagulant events, in some cases involving life-threatening pulmonary thromboembolism (PE). Additional conditions complicating the diagnosis are the presence of risk factors for PE in almost all patients with COVID-19, as well as the overlap of the clinical presentation between PE and COVID-19. Materials and Methods: Тherefore we conducted a single-center study at the Heart and Brain Hospital, Pleven in the period December 2020-February 2021. It included 27 consecutively hospitalized patients with recent pneumonia caused by Covid-19 and clinical presentation referring to PE. The cohort was divided into two groups - with and without a definitive diagnosis of PE, proven by CT pulmoangiography. The aim was to find the indicators that predict the presence of PE in patients with acute or Post-acute COVID-19 conditions. Results: Our results show that part of the ECG criteria - S-wave over 1.5 mm in I lead and aVL (p = 0.007), Q-wave in III and aVF (p = 0.020), as well as the D-dimer as quantitative variable (p = 0.025) proved to be independent predictors of PE. The RV/ LV diameter ratios ≥1.0 as well as right ventricular dysfunction showed sensitivity 62.5%, specificity 100%, positive predictive value 100% and negative such 86.4% to verify the PE diagnosisЛ We suggest that the cut-off value of D-dimer of 1032 ng/ml has an optimal sensitivity (Se) of 87.5%, specificity (Sp) 57.9%, positive a predictive value (PPV) 46.7% and negative predictive value (NPV) of 91.7% for the diagnosis of PE (p = 0.021). Conclusion: Against the background of acute and Post-acute COVID-19 conditions ECG and EchoCG criteria remain predictive of PE. We suggest that a higher D-dimer cut-off value should be applied in COVID-19 and post-COVID-19 patients in order to confirm/dismiss the diagnosis PE.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
N/A
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Local Ethics Committee. The names and institutions of its members are the following: Chairman Prof. Bozhinov - Head of the Department of Neurology, Heart and Brain Center of Excellence, University Hospital, Pleven Deputy Chairman - Prof. Simova, Chief Executive Officer of the Bulgarian Cardiac Institute Head of Cardiology Department Head of a scientific group for post-COVID syndromе, Heart and Brain Center of Excellence, University Hospital, Pleven Secretary Lyuba Miteva - Heart and Brain Center of Excellence, University Hospital, Pleven members Assoc. Prof. Chilingirova - Head of the Clinic of Medical Oncology, Heart and Brain Center of Excellence, University Hospital, Pleven Dr. Krasnaliev - Head of Cardiac Surgery Department, Heart and Brain Center of Excellence, University Hospital, Pleven Dr. Georgi Dimitrov - specialist in orthopedics and traumatology, Heart and Brain Center of Excellence, University Hospital, Pleven MS. Magdalena Voykova - Head nurse in Heart and Brain Center of Excellence, University Hospital, Pleven Diana Zaloznaya, Trade League, Bulgaria - external member Dimitar Stoyanov, lawyer, Tradxe League, Bulgaria - external member. Ethical consent was given by them.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All patients signed an informed consent for pulmoangiography and fibrinolysis, and for personal data analysis. The study protocol is in accordance with the Declaration of Helsinki.